![]() |
The Master of Engineering (MEng) in Pharmaceutical Engineering
New advances in the Human Genome Project (HGP) and automated ultra-high throughput screening have transformed the drug discovery process. Today, researchers are churning out promising new compounds faster than they can be characterized and developed into potentially useful pharmaceuticals. New scientific and engineering approaches requiring a new breed of professionals are needed to streamline and optimize these drug development and manufacturing processes. Associate Professor of Pharmaceutical Sciences Naír Rodríguez-Hornedo and U-M Professor of Chemical Engineering Henry Y. Wang have an answer to industry's needs: a new Master of Engineering (MEng) in Pharmaceutical Engineering. The MEng program, which began instructing students in January, is structured to provide integrated, interdisciplinary didactic and research training in pharmaceutical engineering. The program starts with an interactive video seminar series covering a wide range of topics related to pharmaceutical engineering, from concepts in drug discovery to specific manufacturing processes and regulatory issues. Seminar speakers feature leading experts from academia, industry, and government. One key aspect of the program is its flexibility: students can tailor their curriculum to accommodate their personal career goals. The MEng in Pharmaceutical Engineering may be earned in three ways: Recent pharmacy and chemical engineering graduates and those already working in the field may earn a stand-alone, 30-credit-hour master's degree, emphasizing the interdisciplinary nature of pharmaceutical engineering and lifelong learning. Undergraduates enrolled in chemical engineering at U-M may earn a five-year BSE degree in Chemical Engineering and a MEng in Pharmaceutical Engineering. Undergraduates enrolled in pharmaceutical sciences and related fields at U-M may earn a five-year BS degree in Pharmaceutical Sciences and a MEng in Pharmaceutical Engineering. Course content reflects the most up-to-date advances in the pharmaceutical industry including process engineering and drug discovery; computational biology, chemistry, and engineering; automated high-throughput characterization and analyses; solid-state science and engineering; and novel gene and drug delivery systems. The response from industry and students has been "very enthusiastic," Rodríguez says. A Sept. 17-18 symposium and retreat on "Science and Technology Needs in Pharmaceutical and Life Science-Related Industries," co-hosted by the Colleges of Pharmacy and Engineering, drew a capacity crowd of 120 people and would have brought in even more if space had allowed. Within 12 hours of placing the symposium announcement online, Wang got nearly 50 e-mail inquiries from chemical engineering students. Several East Coast pharmaceutical industry representatives were so intrigued with the program that they braved Hurricane Floyd to attend. The audience - which was evenly divided between industry representatives and University students and faculty - was treated to keynote lectures by Peter Corr, vice president of Warner-Lambert and president of Parke-Davis Research and Development; and Ronald Borchardt, president-elect of the American Association of Pharmaceutical Sciences. Second-day break-out sessions addressed pharmaceutical discovery, characterization and development, product and process development, and manufacturing. The master's degree program is a true partnership with industry, Rodríguez says, citing the pharmaceutical engineering seminar series, which is being underwritten by Pharmacia & Upjohn and Parke-Davis. This partnership also is demonstrated by industry's willingness to offer practical, on-the-job experiences to MEng students through summer internships at such pharmaceutical and life science companies as A. E. Staley Co., Ash Stevens, Inc., BASF, Boehringer-Ingelheim, Hoffman-La Roche, Immuno US/Baxter, MedImmune, Merck & Co., Monsanto/G.D. Searle, Parke-Davis/Warner-Lambert, Pharmacia & Upjohn, Regeneron Pharmaceutical, and Schering-Plough. This year Rodríguez and Wang plan to create an industrial advisory board to match students to developing research areas compatible with their U-M MEng program. In its inaugural form, program enrollment has been limited to 10-12 students per year. This may increase in subsequent terms, depending upon industry and student interest and the level of financial support, explains Rodríguez. One of the things industry found most attractive about the MEng program is its multidisciplinary approach. "Historically, the pharmaceutical and life science-related industries have been very compartmentalized," Rodríguez says. "Industry is now realizing that having scientists and engineers who can navigate among various disciplines, without compromising the rigor of each, is an asset. They get a better return on their investment if students arrive ready to contribute." Even though students in pharmaceutical sciences and chemical engineering are taught material from similar areas and thus share some of the same background, many graduates from these disciplines are not able to bridge disciplines at the applications level. This is unacceptable, Rodríguez says. "There's a revolution going on with the transfer of knowledge from one scientific discipline to another," she observes. "The ability to access information at the molecular level has opened whole new arenas in biology and in materials science. Our challenge is to apply this knowledge to pharmaceutical arenas. In order to achieve this, scientists must be able to communicate with one another." Rodríguez knows of only one other graduate program that offers a degree in pharmaceutical engineering, and that is Rutgers University's Doctoral Training Program in Pharmaceutical Engineering. But that program has a different emphasis than the MEng at U-M, which is co-administered by the Colleges of Pharmacy and Engineering, she explains. Rodríguez and Wang are actively reaching out to other disciplines in the University in order to broaden the base of ideas and provide expert knowledge in new areas of the program. Immediately after the program was announced last fall, Rodríguez received a call from a colleague in applied physics at U-M, and another from a materials science professor whose research and courses are relevant to the MEng in Pharmaceutical Engineering program. "We are inviting the participation of faculty from all units at U-M who are interested in the overall objectives of the program," Rodríguez says. "We hope that medical science, public health, chemistry, engineering, and pharmacy are represented. We are on the threshold of a whole new era in pharmaceutical education." For more on the Master of Engineering in Pharmaceutical Engineering program, point your Web browser to: http://www.engin.umich.edu/dept/che/pharmeng/.
|
|||||
|
Sitemap
| Feedback
| Faculty&Staff Intranet
| University of Michigan
428 Church Street / Ann Arbor, MI 48109-1065 / (734) 764-7312 ©2003 / page last modified: Thursday, 06-Mar-2003 13:55:12 EST |